Enhanced COPD Management in Suspected Lung Cancer Patients

Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates. This study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle. The findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.

NCT Number	NCT07543601
Lead Sponsor	Ditte Krag-Hansen Collaborators: AstraZeneca, Sygehus Lillebaelt
Conditions	COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis), Lung Neoplasm Malignant, Lung Carcinoma, Pulmonary Neoplasms, Pulmonary Neoplasm, Pulmonary Cancers, Pulmonary Cancer +4 more
Enrollment	280 participants
Start Date	2026-03-06
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-22